LRIG3 Antibody [Unconjugated]

LRIG3 was detected in immersion fixed paraffin-embedded sections of human cervical cancer tissue using Goat Anti-Human LRIG3 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF3495) at 3 µg/mL overnight at 4 °C. Tissue was stained using the Anti-Goat HRP-DAB Cell & Tissue Staining Kit (brown; Catalog # CTS008) and counterstained with hematoxylin (blue). Specific staining was localized to cytoplasm of cancer cells. View our protocol for Chromogenic IHC Staining of Paraffin-embedded Tissue Sections.

• Reactivity: Hu
• Applications: WB, IHC
• Clonality: Polyclonal
• Host: Goat
• Conjugate: Unconjugated
• Concentration: LYOPH

LRIG3 Antibody [Unconjugated] Summary

• Immunogen: Mouse myeloma cell line NS0-derived recombinant human LRIG3 isoform 1 (R&D Systems, Catalog # 3495-LR)
  Asp28-Thr807
  Accession # Q6UXM1
• Specificity: Detects human LRIG3 in direct ELISAs and Western blots. In direct ELISAs, less than 1% cross-reactivity with recombinant mouse LRIG1 is observed.
• Source: N/A
• Isotype: IgG
• Clonality: Polyclonal
• Host: Goat
• Gene: LRIG3
• Purity Statement: Antigen Affinity-purified

Applications/Dilutions

• Dilutions:
  • Immunohistochemistry 3-15 ug/mL
  • Western Blot 0.1 ug/mL

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Preservative: No Preservative
• Concentration: LYOPH
• Reconstitution Instructions: Reconstitute at 0.2 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for LRIG3 Antibody [Unconjugated]

• FLJ90440
• KIAA3016
• leucine-rich repeats and immunoglobulin-like domains 3
• leucine-rich repeats and immunoglobulin-like domains protein 3
• LIG-3
• LIG3FLJ26573
• LIRG3
• LRIG3

Background

LRIG3 (leucine-rich repeats and Ig-like domains-3) is a 140 kDa type I transmembrane glycoprotein member of the mammalian LRIG glycoprotein family. This family contains three members who share 45 - 50% amino acid (aa) identity (1). All members contain at least fifteen LRRs, accompanied by two flanking cysteine-rich regions, and three C2-type Ig-like domains in their extracellular domains (ECD) (1). LRIG3 mRNA is widely expressed, with highest levels in stomach, skin, thyroid and small intestine (1). Human LRIG3 is synthesized as a 1120 amino acid (aa) precursor. It contains a 24 aa signal sequence, a 786 aa ECD, a 21 aa transmembrane sequence, and a 289 aa intracellular region. One splice variant exists that has a 19 aa substitution for the first 79 aa of the standard (or long) form. This substitution appears to encode an alternate signal sequence, resulting in a mature protein that lacks the first and part of the second LRR. LRIG1, a related family member, is known to bind the EGF family receptors ErbB1-4, via either its LRR or Ig-like domains. It also binds the ubiquitin ligase, c-Cbl, and promotes ubiquitination, internalization and destruction of these receptors (2, 3). It is not known whether LRIG3 performs similar functions. Within the cell, LRIG3 is expressed in the perinuclear region as well as on the cell surface. Perinuclear location of LRIG3 in grade III and IV astrocytic tumors has been associated with better patient survival (4). Human LRIG3 ECD shows 91%, 92%, 95% and 98% aa identity with mouse, rat, bovine and canine LRIG3 ECD, respectively.

1. Guo, D. et al. (2004) Genomics 84:157.
2. Gur, G. et al. (2004) EMBO J. 23:3270.
3. Laederich, M.B. (2004) J. Biol. Chem. 279:47050.
4. Guo, D. et al. (2006) Acta Neuropathol. (Berl.) 111:238.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for LRIG3 Antibody (AF3495)(1)

Publication using AF3495

• Rafidi , Hanine, Mercado , Francisc, Astudillo , Michael, Fry , William, Saldana , Matthew, Carraway , Kermit L, Sweeney , Colleen Leucine-rich repeat and immunoglobulin domain-containing protein-1 (Lrig1) negative regulatory action toward ErbB receptor tyrosine kinases is opposed by leucine-rich repeat and immunoglobulin domain-containing protein 3 (Lrig3). J Biol Chem, 2013;288(30):21593-605. 2013 [PMID: 23723069] (Western Blot, Human)

Bioinformatics

• Gene Symbol: LRIG3
• Uniprot:
  • Q6UXM1()